Previous 10 | Next 10 |
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will present a p...
2024-05-07 12:15:04 ET H.C. Wainwright analyst issues BUY recommendation for ELDN on May 7, 2024 10:19AM ET. The previous analyst recommendation was Buy. ELDN was trading at $2.2001 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 1...
2024-05-07 08:31:00 ET More on pre-market losers & stocks. Bilibili Stock Downgraded To Sell After Assessing Q4 Earnings Bilibili Inc. (BILI) Q4 2023 Earnings Call Transcript Bilibili Inc. 2023 Q4 - Results - Earnings Call Presentation Bilibili reiterated...
First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of reje...
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has entered into a securities purchase agreement with certain institutional and accredited healthcare investors for a private investment in public equity f...
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is one of today's top gainers. The company's shares have moved 12.64% on the day to $2.09. Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amy...
2024-03-28 17:09:22 ET More on Eledon Pharmaceuticals World’s first pig-to-human kidney transplant performed in U.S Eledon Pharmaceuticals reports recent business milestones Seeking Alpha’s Quant Rating on Eledon Pharmaceuticals Read the full ...
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Ad...
IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12 th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with ...
News, Short Squeeze, Breakout and More Instantly...
Eledon Pharmaceuticals Inc Com Company Name:
ELDN Stock Symbol:
NASDAQ Market:
Eledon Pharmaceuticals Inc Com Website:
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company’s management team will be hosting one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism, on July 9, ...
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m² Mean eGFR measured above 60 mL/min/1.73m...